The immune system's role in sepsis progression, resolution, and long‐term outcome

MJ Delano, PA Ward - Immunological reviews, 2016 - Wiley Online Library
Sepsis occurs when an infection exceeds local tissue containment and induces a series of
dysregulated physiologic responses that result in organ dysfunction. A subset of patients …

[HTML][HTML] Sepsis: evolving concepts and challenges

R Salomão, BL Ferreira, MC Salomão… - Brazilian Journal of …, 2019 - SciELO Brasil
Sepsis remains a major cause of morbidity and mortality worldwide, with increased burden
in low-and middle-resource settings. The role of the inflammatory response in the …

Nitric oxide and peroxynitrite in health and disease

P Pacher, JS Beckman, L Liaudet - Physiological reviews, 2007 - journals.physiology.org
The discovery that mammalian cells have the ability to synthesize the free radical nitric oxide
(NO) has stimulated an extraordinary impetus for scientific research in all the fields of …

The pathophysiology and treatment of sepsis

RS Hotchkiss, IE Karl - New England journal of medicine, 2003 - Mass Medical Soc
Sepsis is the leading cause of death in critically ill patients in the United States. Yet the
individual host response to septicemia is variable, depending on the patient's immune …

Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer

A Juvekar, LN Burga, H Hu, EP Lunsford, YH Ibrahim… - Cancer discovery, 2012 - AACR
There is a need to improve treatments for metastatic breast cancer. Here, we show the
activation of the phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase …

Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function

JW Elrod, JW Calvert, J Morrison… - Proceedings of the …, 2007 - National Acad Sciences
The recent discovery that hydrogen sulfide (H2S) is an endogenously produced gaseous
second messenger capable of modulating many physiological processes, much like nitric …

The therapeutic potential of poly (ADP-ribose) polymerase inhibitors

L Virag, C Szabó - Pharmacological reviews, 2002 - ASPET
Poly (ADP-ribose) polymerase-1 (PARP-1) is a member of the PARP enzyme family
consisting of PARP-1 and several recently identified novel poly (ADP-ribosylating) enzymes …

Therapeutic applications of PARP inhibitors: anticancer therapy and beyond

NJ Curtin, C Szabo - Molecular aspects of medicine, 2013 - Elsevier
The aim of this article is to describe the current and potential clinical translation of
pharmacological inhibitors of poly (ADP-ribose) polymerase (PARP) for the therapy of …

Opportunities for the repurposing of PARP inhibitors for the therapy of non‐oncological diseases

NA Berger, VC Besson, AH Boulares… - British journal of …, 2018 - Wiley Online Library
The recent clinical availability of the PARP inhibitor olaparib (Lynparza) opens the door for
potential therapeutic repurposing for non‐oncological indications. Considering (a) the …

PARP-1 and gene regulation: progress and puzzles

WL Kraus, MO Hottiger - Molecular aspects of medicine, 2013 - Elsevier
Abstract Poly (ADP-ribose) polymerase-1 (PARP-1), also referred to as ADP-
ribosyltransferase Diphtheria toxin-like 1 (ARTD1), is an abundant nuclear protein that plays …